0.00

100.00% -9.71

Fibrogen Inc (FGEN)

Overview News Price History Option Chain Financials Why FGEN Down? Discussions Forecast

Fibrogen Inc stock is traded at $0.00, with a volume of 0. It is down -100.00% in the last 24 hours and down -100.00% over the past month. FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.

Previous Close:

$9.71

Open:

24h Volume:

Relative Volume:

0.00

Market Cap:

$39.28M

Revenue:

$147.75M

Net Income/Loss:

$-284.23M

P/E Ratio:

0.00

EPS:

-2.93

Net Cash Flow:

$-317.54M

1W Performance:

-100.00%

1M Performance:

-100.00%

6M Performance:

-100.00%

1Y Performance:

-100.00%

1-Day Range:

$0.00

1-Week Range:

$0.00

52-Week Range:

$0.00

$12.60

Fibrogen Inc Stock (FGEN) Company Profile

Name

Fibrogen Inc

Sector

Healthcare (1109)

Industry

Biotechnology (618)

Phone

415-978-1200

Address

350 BAY STREET, SAN FRANCISCO, CA

Employee

225

Twitter

@FibroGenInc

Next Earnings Date

2025-03-17

Latest SEC Filings

FGEN's Discussions on Twitter

Compare FGEN vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
FGEN Fibrogen Inc	0.00	39.28M	147.75M	-284.23M	-317.54M	-2.93
VRTX Vertex Pharmaceuticals Inc	436.98	113.59B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	603.43	64.45B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	837.56	51.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	299.22	40.32B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	162.46	33.48B	742.00K	-1.37B	-1.07B	-7.0731

Fibrogen Inc Stock (FGEN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-08-23	Downgrade	BofA Securities	Neutral → Underperform
Jun-26-23	Downgrade	BofA Securities	Buy → Neutral
Jun-26-23	Downgrade	Raymond James	Outperform → Mkt Perform
Jun-26-23	Downgrade	Stifel	Buy → Hold
Jun-26-23	Downgrade	William Blair	Outperform → Mkt Perform
Jun-02-23	Upgrade	Stifel	Hold → Buy
Jan-31-23	Upgrade	William Blair	Mkt Perform → Outperform
Jan-26-23	Upgrade	Raymond James	Mkt Perform → Outperform
Jan-05-23	Upgrade	BofA Securities	Neutral → Buy
Sep-22-21	Downgrade	Goldman	Neutral → Sell
Aug-20-21	Upgrade	Raymond James	Underperform → Mkt Perform
Jul-16-21	Downgrade	BofA Securities	Buy → Neutral
Jul-16-21	Downgrade	Stifel	Buy → Hold
Apr-07-21	Downgrade	H.C. Wainwright	Buy → Neutral
Apr-07-21	Downgrade	Mizuho	Buy → Neutral
Mar-31-21	Upgrade	BofA Securities	Neutral → Buy
Mar-02-21	Downgrade	Jefferies	Buy → Hold
Feb-01-21	Initiated	H.C. Wainwright	Buy
Oct-26-20	Initiated	Raymond James	Underperform
Jul-10-20	Resumed	Stifel	Buy
May-01-20	Initiated	Cowen	Market Perform
Apr-27-20	Initiated	BofA/Merrill	Neutral
May-29-19	Resumed	Goldman	Neutral
May-10-19	Downgrade	William Blair	Outperform → Mkt Perform
Apr-12-19	Initiated	Piper Jaffray	Neutral
Feb-11-19	Resumed	Stifel	Buy
Dec-19-18	Upgrade	Citigroup	Neutral → Buy
Aug-08-17	Reiterated	Leerink Partners	Outperform
Aug-08-17	Reiterated	Stifel	Buy
Jul-21-17	Downgrade	Goldman	Buy → Neutral
Jul-11-17	Initiated	Jefferies	Buy
Feb-11-16	Upgrade	Credit Suisse	Neutral → Outperform
Jan-21-16	Initiated	Credit Suisse	Neutral
Dec-04-15	Initiated	Citigroup	Buy
Sep-23-15	Initiated	Lake Street	Hold
Jul-29-15	Initiated	Citigroup	Buy
Jul-20-15	Upgrade	Goldman	Neutral → Buy
Dec-09-14	Initiated	Stifel	Buy

View All

Fibrogen Inc Stock (FGEN) Latest News

May 21, 2026

FibroGen Inc stock (US3156631046): volatility after Nasdaq delisting and Kynbio merger plans - AD HOC NEWS

May 21, 2026

May 18, 2026

KYNTRA BIO (KYNB) CEO Thane Wettig purchases 2,800 shares at $7.09 - Stock Titan

May 18, 2026

May 15, 2026

Armistice Capital (FGEN) reports 400,000-share, 9.88% position (May 2026) - Stock Titan

May 15, 2026

May 13, 2026

Health News Roundup: FibroGen's neuromuscular disorder therapy fails late-stage study; Merck sues US government to halt Medicare drug price negotiation and more - Devdiscourse

May 13, 2026